Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus和Barinthus Bio宣佈了Im-Prove II試驗的新數據,顯示尼伏單抗的添加提高了慢性乙型肝炎患者Hbsag丟失的比率。
Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus和Barinthus Bio宣佈了Im-Prove II試驗的新數據,顯示尼伏單抗的添加提高了慢性乙型肝炎患者Hbsag丟失的比率。
使用瀏覽器的分享功能,分享給你的好友吧